A role for β-dystroglycan in the organization and structure of the nucleus in myoblasts

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 3, 2013, Pages 698-711

  Martínez Vieyra, Ivette A ^a   Vásquez Limeta, Alejandra ^a   González Ramírez, Ricardo ^b   Morales Lázaro, Sara L ^c   Mondragón, Mónica ^a   Mondragón, Ricardo ^a   Ortega, Arturo ^a   Winder, Steve J ^d   Cisneros, Bulmaro ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Dystroglycan; Emerin; Nuclear envelope; Nuclear lamins; Nucleoli

Indexed keywords

BETA DYSTROGLYCAN; CYCLOHEXIMIDE; EMERIN; LAMIN A; LAMIN B1; LAMIN C; MESSENGER RNA; NUCLEAR PROTEIN; P80 COILIN; PROTEIN NOPP140; PROTEIN P80; PROTEIN SC35; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CELL ULTRASTRUCTURE; CELLULAR DISTRIBUTION; CENTROSOME; COILED BODY; DOWN REGULATION; ELECTRON MICROSCOPY; GENE EXPRESSION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; MYOBLAST; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLICING SPECKLE;

ANIMALS; BLOTTING, WESTERN; CELL NUCLEOLUS; CELL NUCLEUS; CELLS, CULTURED; COILED BODIES; DYSTROGLYCANS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOPRECIPITATION; LAMIN TYPE B; MEMBRANE PROTEINS; MICE; MUSCLE, SKELETAL; MYOBLASTS; NUCLEAR ENVELOPE; NUCLEAR PROTEINS; PHOSPHOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84872029076     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.11.019     Document Type: Article

References (64)

1. Gerace L., Huber M.D. Nuclear lamina at the crossroads of the cytoplasm and nucleus. J. Struct. Biol. 2012, 177:24-31.
2. Crisp M., Burke B. The nuclear envelope as an integrator of nuclear and cytoplasmic architecture. FEBS Lett. 2008, 582:2023-2032.
3. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3:802-808.
4. Grummt I. Actin and myosin as transcription factors. Curr. Opin. Genet. Dev. 2006, 16:191-196.
5. Hervy M., Hoffman L., Beckerle M.C. From the membrane to the nucleus and back again: bifunctional focal adhesion proteins. Curr. Opin. Cell Biol. 2006, 18:524-532.
6. Oma Y., Harata M. Actin-related proteins localized in the nucleus: from discovery to novel roles in nuclear organization. Nucleus 2011, 2:38-46.
7. Ervasti J.M., Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 1993, 122:809-823.
8. Di Stasio E., Sciandra F., Maras B., Di Tommaso F., Petrucci T.C., Giardina B., Brancaccio A. Structural and functional analysis of the N-terminal extracellular region of beta-dystroglycan. Biochem. Biophys. Res. Commun. 1999, 266:274-278.
9. Henry M.D., Campbell K.P. Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Curr. Opin. Cell Biol. 1996, 8:625-631.
10. Winder S.J. The complexities of dystroglycan. Trends Biochem. Sci. 2001, 26:118-124.
11. Ilsley J.L., Sudol M., Winder S.J. The interaction of dystrophin with beta-dystroglycan is regulated by tyrosine phosphorylation. Cell. Signal. 2001, 13:625-632.
12. James M., Nuttall A., Ilsley J.L., Ottersbach K., Tinsley J.M., Sudol M., Winder S.J. Adhesion-dependent tyrosine phosphorylation of (beta)-dystroglycan regulates its interaction with utrophin. J. Cell Sci. 2000, 113(Pt 10):1717-1726.
13. Sotgia F., Lee H., Bedford M.T., Petrucci T., Sudol M., Lisanti M.P. Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins. Biochemistry 2001, 40:14585-14592.
14. Spence H.J., Dhillon A.S., James M., Winder S.J. Dystroglycan, a scaffold for the ERK-MAP kinase cascade. EMBO Rep. 2004, 5:484-489.
15. Batchelor C.L., Higginson J.R., Chen Y.J., Vanni C., Eva A., Winder S.J. Recruitment of Dbl by ezrin and dystroglycan drives membrane proximal Cdc42 activation and filopodia formation. Cell Cycle 2007, 6:353-363.
16. Spence H.J., Chen Y.J., Batchelor C.L., Higginson J.R., Suila H., Carpen O., Winder S.J. Ezrin-dependent regulation of the actin cytoskeleton by beta-dystroglycan. Hum. Mol. Genet. 2004, 13:1657-1668.
17. Rando T.A. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001, 24:1575-1594.
18. Langenbach K.J., Rando T.A. Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 2002, 26:644-653.
19. Thompson O., Moore C.J., Hussain S.A., Kleino I., Peckham M., Hohenester E., Ayscough K.R., Saksela K., Winder S.J. Modulation of cell spreading and cell-substrate adhesion dynamics by dystroglycan. J. Cell Sci. 2010, 123:118-127.
20. Moore C.J., Winder S.J. Dystroglycan versatility in cell adhesion: a tale of multiple motifs. Cell Commun. Signal 2010, 8:3.
21. Fuentes-Mera L., Rodriguez-Munoz R., Gonzalez-Ramirez R., Garcia-Sierra F., Gonzalez E., Mornet D., Cisneros B. Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix. Exp. Cell Res. 2006, 312:3023-3035.
22. Gonzalez-Ramirez R., Morales-Lazaro S.L., Tapia-Ramirez V., Mornet D., Cisneros B. Nuclear and nuclear envelope localization of dystrophin Dp71 and dystrophin-associated proteins (DAPs) in the C2C12 muscle cells: DAPs nuclear localization is modulated during myogenesis. J. Cell. Biochem. 2008, 105:735-745.
23. Lara-Chacon B., de Leon M.B., Leocadio D., Gomez P., Fuentes-Mera L., Martinez-Vieyra I., Ortega A., Jans D.A., Cisneros B. Characterization of an Importin alpha/beta-recognized nuclear localization signal in beta-dystroglycan. J. Cell. Biochem. 2010, 110:706-717.
24. Oppizzi M.L., Akhavan A., Singh M., Fata J.E., Muschler J.L. Nuclear translocation of beta-dystroglycan reveals a distinctive trafficking pattern of autoproteolyzed mucins. Traffic 2008, 9:2063-2072.
25. Rivier F., Robert A., Hugon G., Bonet-Kerrache A., Nigro V., Fehrentz J.A., Martinez J., Mornet D. Dystrophin and utrophin complexed with different associated proteins in cardiac Purkinje fibres. Histochem. J. 1999, 31:425-432.
26. Rodriguez-Munoz R., Villarreal-Silva M., Gonzalez-Ramirez R., Garcia-Sierra F., Mondragon M., Mondragon R., Cerna J., Cisneros B. Neuronal differentiation modulates the dystrophin Dp71d binding to the nuclear matrix. Biochem. Biophys. Res. Commun. 2008, 375:303-307.
27. Cerna J., Cerecedo D., Ortega A., Garcia-Sierra F., Centeno F., Garrido E., Mornet D., Cisneros B. Dystrophin Dp71f associates with the beta1-integrin adhesion complex to modulate PC12 cell adhesion. J. Mol. Biol. 2006, 362:954-965.
28. Cerecedo D., Cisneros B., Suarez-Sanchez R., Hernandez-Gonzalez E., Galvan I. beta-Dystroglycan modulates the interplay between actin and microtubules in human-adhered platelets. Br. J. Haematol. 2008, 141:517-528.
29. Cluchague N., Moreau C., Rocher C., Pottier S., Leray G., Cherel Y., Le Rumeur E. beta-Dystroglycan can be revealed in microsomes from mdx mouse muscle by detergent treatment. FEBS Lett. 2004, 572:216-220.
30. Martin L.T., Glass M., Dosunmu E., Martin P.T. Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors. Hum. Pathol. 2007, 38:1657-1668.
31. Fernandez K., Serinagaoglu Y., Hammond S., Martin L.T., Martin P.T. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am. J. Pathol. 2010, 176:416-434.
32. Chen Y.J., Spence H.J., Cameron J.M., Jess T., Ilsley J.L., Winder S.J. Direct interaction of beta-dystroglycan with F-actin. Biochem. J. 2003, 375:329-337.
33. Favreau C., Dubosclard E., Ostlund C., Vigouroux C., Capeau J., Wehnert M., Higuet D., Worman H.J., Courvalin J.C., Buendia B. Expression of lamin A mutated in the carboxyl-terminal tail generates an aberrant nuclear phenotype similar to that observed in cells from patients with Dunnigan-type partial lipodystrophy and Emery-Dreifuss muscular dystrophy. Exp. Cell Res. 2003, 282:14-23.
34. Lammerding J., Fong L.G., Ji J.Y., Reue K., Stewart C.L., Young S.G., Lee R.T. Lamins A and C but not lamin B1 regulate nuclear mechanics. J. Biol. Chem. 2006, 281:25768-25780.
35. Muchir A., Medioni J., Laluc M., Massart C., Arimura T., van der Kooi A.J., Desguerre I., Mayer M., Ferrer X., Briault S., Hirano M., Worman H.J., Mallet A., Wehnert M., Schwartz K., Bonne G. Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations. Muscle Nerve 2004, 30:444-450.
36. Yang S.H., Bergo M.O., Toth J.I., Qiao X., Hu Y., Sandoval S., Meta M., Bendale P., Gelb M.H., Young S.G., Fong L.G. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10291-10296.
37. Salpingidou G., Smertenko A., Hausmanowa-Petrucewicz I., Hussey P.J., Hutchison C.J. A novel role for the nuclear membrane protein emerin in association of the centrosome to the outer nuclear membrane. J. Cell Biol. 2007, 178:897-904.
38. Vaughan A., Alvarez-Reyes M., Bridger J.M., Broers J.L., Ramaekers F.C., Wehnert M., Morris G.E., Whitfield W.G.F., Hutchison C.J. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. J. Cell Sci. 2001, 114:2577-2590.
39. Delbarre E., Tramier M., Coppey-Moisan M., Gaillard C., Courvalin J.C., Buendia B. The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers. Hum. Mol. Genet. 2006, 15:1113-1122.
40. Goldberg M.W., Huttenlauch I., Hutchison C.J., Stick R. Filaments made from A- and B-type lamins differ in structure and organization. J. Cell Sci. 2008, 121:215-225.
41. Fairley E.A., Kendrick-Jones J., Ellis J.A. The Emery-Dreifuss muscular dystrophy phenotype arises from aberrant targeting and binding of emerin at the inner nuclear membrane. J. Cell Sci. 1999, 112(Pt 15):2571-2582.
42. Lammerding J., Hsiao J., Schulze P.C., Kozlov S., Stewart C.L., Lee R.T. Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J. Cell Biol. 2005, 170:781-791.
43. Higginson J.R., Thompson O., Winder S.J. Targeting of dystroglycan to the cleavage furrow and midbody in cytokinesis. Int. J. Biochem. Cell Biol. 2008, 40:892-900.
44. Sgambato A., Camerini A., Faraglia B., Pavoni E., Montanari M., Spada D., Losasso C., Brancaccio A., Cittadini A. Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells. Cancer Biol. Ther. 2004, 3:967-975.
45. Nigg E.A., Stearns T. The centrosome cycle: centriole biogenesis, duplication and inherent asymmetries. Nat. Cell Biol. 2011, 13:1154-1160.
46. Cross S.S., Lippitt J., Mitchell A., Hollingsbury F., Balasubramanian S.P., Reed M.W., Eaton C., Catto J.W., Hamdy F., Winder S.J. Expression of beta-dystroglycan is reduced or absent in many human carcinomas. Histopathology 2008, 53:561-566.
47. Parberry-Clark C., Bury J.P., Cross S.S., Winder S.J. Loss of dystroglycan function in oesophageal cancer. Histopathology 2011, 59:180-187.
48. Ervasti J.M., Sonnemann K.J. Biology of the striated muscle dystrophin-glycoprotein complex. Int. Rev. Cytol. 2008, 265:191-225.
49. Darras B.T., Blattner P., Harper J.F., Spiro A.J., Alter S., Francke U. Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and BglII exon-containing fragment maps, meiotic and mitotic origin of the mutations. Am. J. Hum. Genet. 1988, 43:620-629.
50. Daniele N., Richard I., Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int. J. Biochem. Cell Biol. 2007, 39:1608-1624.
51. Hara Y., Balci-Hayta B., Yoshida-Moriguchi T., Kanagawa M., Beltran-Valero de Bernabe D., Gundesli H., Willer T., Satz J.S., Crawford R.W., Burden S.J., Kunz S., Oldstone M.B., Accardi A., Talim B., Muntoni F., Topaloglu H., Dincer P., Campbell K.P. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med. 2011, 364:939-946.
52. Godfrey C., Clement E., Abbs S., Muntoni F. Exclusion of WWP1 mutations in a cohort of dystroglycanopathy patients. Muscle Nerve 2011, 44:388-392.
53. Broers J.L., Peeters E.A., Kuijpers H.J., Endert J., Bouten C.V., Oomens C.W., Baaijens F.P., Ramaekers F.C. Decreased mechanical stiffness in LMNA-/- cells is caused by defective nucleo-cytoskeletal integrity: implications for the development of laminopathies. Hum. Mol. Genet. 2004, 13:2567-2580.
54. Hutchison C.J., Alvarez-Reyes M., Vaughan O.A. Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes?. J. Cell Sci. 2001, 114:9-19.
55. Maraldi N.M., Capanni C., Cenni V., Fini M., Lattanzi G. Laminopathies and lamin-associated signaling pathways. J. Cell. Biochem. 2011, 112:979-992.
56. Worman H.J., Fong L.G., Muchir A., Young S.G. Laminopathies and the long strange trip from basic cell biology to therapy. J. Clin. Invest. 2009, 119:1825-1836.
57. Wilson K.L. The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol. 2000, 10:125-129.
58. Cohn R.D., Henry M.D., Michele D.E., Barresi R., Saito F., Moore S.A., Flanagan J.D., Skwarchuk M.W., Robbins M.E., Mendell J.R., Williamson R.A., Campbell K.P. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 2002, 110:639-648.
59. Moore S.A., Saito F., Chen J., Michele D.E., Henry M.D., Messing A., Cohn R.D., Ross-Barta S.E., Westra S., Williamson R.A., Hoshi T., Campbell K.P. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 2002, 418:422-425.
60. Satz J.S., Philp A.R., Nguyen H., Kusano H., Lee J., Turk R., Riker M.J., Hernandez J., Weiss R.M., Anderson M.G., Mullins R.F., Moore S.A., Stone E.M., Campbell K.P. Visual impairment in the absence of dystroglycan. J. Neurosci. 2009, 29:13136-13146.
61. Miller G., Moore C.J., Terry R., La Riviere T., Mitchell A., Piggott R., Dear T.N., Wells D.J., Winder S.J. Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse. Hum. Mol. Genet. 2012, 21:4508-4520.
62. Tang C.W., Maya-Mendoza A., Martin C., Zeng K., Chen S., Feret D., Wilson S.A., Jackson D.A. The integrity of a lamin-B1-dependent nucleoskeleton is a fundamental determinant of RNA synthesis in human cells. J. Cell Sci. 2008, 121:1014-1024.
63. Martin C., Chen S., Maya-Mendoza A., Lovric J., Sims P.F., Jackson D.A. Lamin B1 maintains the functional plasticity of nucleoli. J. Cell Sci. 2009, 122:1551-1562.
64. Mitchell A., Mathew G., Jiang T., Hamdy F.C., Cross S.S., Eaton C., Winder S.J. Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer. Prostate 2012, (Epub ahead of print). 10.1002/pros.22581.